Myriad Genetics (MYGN) 10-K 10 Aug 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2016	Aug. 01, 2016	Dec. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	899,923
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		69,134,651
Entity Public Float			$ 3,028,034,947

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 68.5	$ 64.1
Marketable investment securities	90.5	80.7
Prepaid expenses	18.4	12.5
Inventory	38.3	25.1
Trade accounts receivable, less allowance for doubtful accounts of $6.8 in 2016 and $7.6 in 2015	91.7	85.8
Deferred taxes		13.5
Prepaid taxes	3.8
Other receivables	3.3	1.9
Total current assets	314.5	283.6
Property, plant and equipment, net	58.3	67.2
Long-term marketable investment securities	79.9	40.6
Intangibles, net	227.5	192.6
Goodwill	195.3	177.2
Other assets	5	5
Total assets	880.5	766.2
Current liabilities:
Accounts payable	21.1	21.1
Accrued liabilities	49.5	46.1
Deferred revenue	1.7	1.5
Total current liabilities	72.3	68.7
Unrecognized tax benefits	24	26.4
Other long-term liabilities	18.2	8.8
Long-term deferred taxes	17.9	0.2
Total liabilities	132.4	104.1
Commitments and contingencies
Stockholders' equity:
Common stock, 69.1 and 68.9 shares outstanding at June 30, 2016 and 2015 respectively	0.7	0.7
Additional paid-in capital	830.1	745.4
Accumulated other comprehensive loss	(9.5)	(7)
Accumulated deficit	(73.2)	(77)
Total stockholders' equity	748.1	662.1
Total liabilities and stockholders' equity	$ 880.5	$ 766.2

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 6.8	$ 7.6
Common stock, shares outstanding	69.1	68.9

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Molecular diagnostic testing	$ 705.7	$ 695.5	$ 748.2
Pharmaceutical and clinical services	48.1	27.6	30
Total revenue	753.8	723.1	778.2
Costs and expenses:
Cost of molecular diagnostic testing	132.8	132.8	96.1
Cost of pharmaceutical and clinical services	24.5	14.6	13.1
Research and development expense	70.6	75.5	67.5
Selling, general, and administrative expense	359.1	366	327.1
Total costs and expenses	587	588.9	503.8
Operating income	166.8	134.2	274.4
Other income (expense):
Interest income	0.9	0.4	5.4
Other	1.2	0.3	(2)
Total other income:	2.1	0.7	3.4
Income before income tax	168.9	134.9	277.8
Income tax provision	43.6	54.7	101.6
Net income	$ 125.3	$ 80.2	$ 176.2
Earnings per share:
Basic	$ 1.79	$ 1.12	$ 2.33
Diluted	$ 1.71	$ 1.08	$ 2.25
Weighted average shares outstanding:
Basic	70	71.3	75.7
Diluted	73.4	74.5	78.2

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 125.3	$ 80.2	$ 176.2
Unrealized gain (loss) on available-for-sale securities, net of tax	0.3	(0.3)	0.6
Change in pension liability	(0.2)
Change in foreign currency translation adjustment	(2.6)	(5.2)	(1.7)
Comprehensive income	$ 122.8	$ 74.7	$ 175.1

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive loss	Retained earnings (accumulated deficit)
Beginning Balance at Jun. 30, 2013	$ 728.6	$ 0.8	$ 697.3	$ (0.4)	$ 30.9
Issuance of common stock under employee stock purchase plan	64.8		64.8
Share-based payment expense	27.1		27.1
Share-based compensation tax benefits	11.1		11.1
Repurchase and retirement of common stock	(287.7)	(0.1)	(82.5)		(205.1)
Net income	176.2				176.2
Other comprehensive loss, net of tax	(1.1)			(1.1)
Ending Balance at Jun. 30, 2014	719	0.7	717.8	(1.5)	2
Issuance of common stock under employee stock purchase plan	30		30
Share-based payment expense	45.7		45.7
Share-based compensation tax benefits	3.4		3.4
Repurchase and retirement of common stock	(210.7)		(51.5)		(159.2)
Net income	80.2				80.2
Other comprehensive loss, net of tax	(5.5)			(5.5)
Ending Balance at Jun. 30, 2015	662.1	0.7	745.4	(7)	(77)
Issuance of common stock under employee stock purchase plan	94.3		94.3
Share-based payment expense	31.6		31.6
Repurchase and retirement of common stock	(162.6)		(41.2)		(121.4)
Net income	125.3				125.3
Other comprehensive loss, net of tax	(2.5)			(2.5)
Ending Balance at Jun. 30, 2016	$ 748.1	$ 0.7	$ 830.1	$ (9.5)	$ (73.2)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 125.3	$ 80.2	$ 176.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	26.7	25	13.8
Loss (gain) on disposition of assets	(0.9)	0.5	0.9
Share-based compensation expense	31.6	45.7	27.1
Bad debt expense	33.3	31.5	39.2
Deferred income taxes	18.1	(0.4)	8.1
Unrecognized tax benefits	(2.4)	2.1	(0.7)
Accreted interest on note receivable			(3.3)
Excess tax benefit from share-based compensation		(3.4)	(11.1)
Changes in assets and liabilities:
Prepaid expenses	(7.2)	(5.5)	(5.5)
Trade accounts receivable	(39.2)	(34.4)	(24.4)
Other receivables	(0.9)	2.5	(1.9)
Inventory	(14.6)	(0.8)	(15.8)
Prepaid taxes	(3.8)	13.6	(12.9)
Accounts payable		(3.1)	(1.5)
Accrued liabilities	0.5	(13.4)	3.1
Deferred revenue	(0.2)	0.4	(1.1)
Net cash provided by operating activities	166.3	140.5	190.2
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(5)	(23.9)	(14.3)
Acquisitions, net of cash acquired	(37)	(20.1)	(223.5)
Purchases of marketable investment securities	(164.5)	(80.7)	(161.8)
Proceeds from maturities and sales of marketable investment securities	115.1	165.6	382.5
Net cash provided by (used in) investing activities	(91.4)	40.9	(17.1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans	94.3	30	64.8
Excess tax benefit from share-based compensation		3.4	11.1
Repurchase and retirement of common stock	(162.6)	(210.7)	(287.7)
Net cash used in financing activities	(68.3)	(177.3)	(211.8)
Effect of foreign exchange rates on cash and cash equivalents	(2.2)	(4.8)	(0.6)
Net (decrease) increase in cash and cash equivalents	4.4	(0.7)	(39.3)
Cash and cash equivalents at beginning of year	64.1	64.8	104.1
Cash and cash equivalents at end of year	$ 68.5	$ 64.1	$ 64.8

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine tests. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company generates revenue by performing molecular diagnostic tests as well as by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah. The consolidated financial statements of the Company are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP. Certain reclassifications have been made to prior period amounts to conform to the current period presentation. A reclassification of $0.6 from proceeds from maturities and sales of marketable securities was made to reflect the effect of foreign exchange rates on cash and cash equivalents in the condensed consolidated statement of cash flows and for the fiscal year ended June 30, 2014 and a reclassification of $0.6 from other receivables to trade accounts receivable in the condensed consolidated balance sheet for fiscal year ended June 30, 2014 to conform to the current-year presentation. Marketable Investment Securities The Company has classified its marketable investment securities as available-for-sale. Available-for-sale investment securities with remaining maturities of greater than one year are classified as long-term. Available-for-sale investment securities with remaining maturities of one year or less are classified as short-term. Available-for-sale investment securities with remaining maturities of less than three months at the time of purchase are classified as cash equivalents. Marketable securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported using the specific-identification method. Dividend and interest income are recognized when earned. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. We review several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) our ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the fiscal years ended June 30, 2016, 2015 and 2014. Inventory Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers. Trade Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are comprised of amounts due from sales of the Company’s molecular diagnostic tests and pharmaceutical and clinical services and are recorded at the invoiced amount, net of discounts and contractual allowances. The allowance for doubtful accounts is based on the Company’s best estimate of the amount of probable losses in the Company’s existing accounts receivable, which is based on historical write-off experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral. Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to fifteen years. Repairs and maintenance costs are charged to expense as incurred. Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses, technology and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Goodwill Goodwill is tested for impairment on an annual basis as of April 1 and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill was first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a two-step impairment analysis is performed. The first step involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the second step of the process involves a comparison of the fair value and the carrying amount of the goodwill of that reporting unit. If the carrying amount of the goodwill of the reporting unit exceeds the fair value of that goodwill, an impairment loss would be recognized in an amount equal to the excess of carrying value over fair value. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results. Revenue Recognition Molecular diagnostic testing revenue is recognized when persuasive evidence of an agreement exists, results have been communicated to the patient, the fee is fixed or determinable, and collection is reasonably assured. Revenue from the sale of molecular diagnostic tests and related marketing agreements is recorded at the invoiced amount net of any discounts or contractual allowances. Pharmaceutical and clinical service revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed and or determinable, when the service has been completed and the results of the tests/service are provided to the customer, and collectability is reasonably assured. In addition, the Company’s wholly owned subsidiary, Myriad RBM, has received national, state, foreign government and private foundation grants and contracts. Revenue associated with these grants and contracts is recognized in the period in which qualifying costs for the services by the grants and contracts are incurred and the related grant or contract fee is earned. Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows. Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2016 2015 2014 Denominator: Weighted-average shares outstanding used to compute basic EPS 70.0 71.3 75.7 Effect of dilutive stock options 3.4 3.2 2.5 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 73.4 74.5 78.2 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2016 2015 2014 Anti-dilutive options and RSUs excluded from EPS computation — — — Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ (deficit) equity. The following table shows the cumulative translation adjustments included in other comprehensive income: Balance at June 30, 2015 $ (7.0 ) Period translation adjustments (2.6 ) Ending balance June 30, 2016 (9.6 ) Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation—Stock Compensation (Topic 718) (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. ASU 2016-09 will be effective for the Company beginning in its first quarter of 2018. We adopted this guidance during the current fiscal year. For discussion of impact see note 10 to the financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its first quarter of 2020 and early adoption is permitted. We are currently evaluating the timing of its adoption and the impact of adopting the new lease standard on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, which requires all deferred tax assets and liabilities to be classified as non-current. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016. Early adoption is permitted. We adopted this guidance in the current fiscal year. Refer to note 10 for discussion on the impact of adoption. In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, “Revenue from Contracts with Customers.” Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. In July 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted for interim and annual periods beginning after the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Business Acquisitions

Business Acquisitions	12 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Acquisitions	2. BUSINESS ACQUISITIONS Sividon On May 31, 2016 we completed the acquisition of Sividon Diagnostics GmbH (“Sividon”), a leading breast cancer prognostic company with cash paid and total cash consideration transferred of $39.0 upfront and the potential for €15.0 ($16.7 converted at the June 30, 2016 period end exchange rate) in additional performance-based milestones. Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their fair values at the acquisition date as set forth below. We believe the acquisition brings us the best-in-class breast cancer prognostic test and strengthens our market leading oncology portfolio of high value personalized medicine products which can be expanded internationally as well as brought to the US market. These factors contributed to consideration transferred in excess of the fair value of Sividon’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. The goodwill related to the purchase is not tax deductible. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The preliminary allocation of the consideration transferred is based on a preliminary valuation and is subject to potential adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities and the fair value of equipment, as well as tax-related matters, including tax basis of acquired assets and liabilities in the foreign jurisdiction. During the measurement period, the Company may record adjustments to the provisional amounts recognized in the Company’s initial accounting for the acquisition. The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). Estimated Fair Current assets $ 2.7 Intangible assets 46.2 Equipment 0.3 Goodwill 17.7 Current liabilites (15.4 ) Total fair value purchase price $ 51.5 Less: Contingent consideration (10.5 ) Less: Cash acquired (2.0 ) Total cash consideration transferred $ 39.0 The acquisition of Sividon has been deemed insignificant in relation to the consolidated financials. As such, proforma financial information will not be provided. German Clinic On February 27, 2015, the Company completed the acquisition of privately-held Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) approximately 15 miles from the Company’s European laboratories in Munich, Germany. The cash paid and total consideration transferred to acquire the Clinic was $20.1. Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their fair values at the acquisition date as set forth below. The Company believes acquisition of the Clinic should facilitate the Company’s penetration into the German molecular diagnostic market. The Clinic will allow the Company to directly negotiate reimbursement with government and private insurance providers for its tests in the German market and collaborate with hospitals and physician groups. These factors contributed to consideration transferred in excess of the fair value of the Clinic’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. Under German tax law the goodwill related to the purchase of the clinic is deductible and will be amortized for tax purposes over 15 years. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. This acquisition accounting is now final. Fair Value Current assets $ 3.1 Real property 20.7 Equipment 1.6 Goodwill 8.7 Current liabilites (4.4 ) Long-term liabilities (9.6 ) Total purchase price $ 20.1 During the year ended June 30, 2016 there was an adjustment to long-term liabilities. The long-term liabilities increased by approximately $0.6 due to information obtained from the third party actuarial analysis of the pension obligation which increased goodwill by the same amount.

Marketable Investment Securitie

Marketable Investment Securities	12 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Marketable Investment Securities	3. MARKETABLE INVESTMENT SECURITIES The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2016 and 2015 were as follows: Amortized Gross Gross Estimated At June 30, 2016: Cash and cash equivalents: Cash $ 66.1 $ — $ — $ 66.1 Cash equivalents 2.4 — — 2.4 Total cash and cash equivalents 68.5 — — 68.5 Available-for-sale: Corporate bonds and notes 50.8 0.2 — 51.0 Municipal bonds 85.4 0.2 — 85.6 Federal agency issues 25.5 — — 25.5 US government securities 8.2 0.1 — 8.3 Total $ 238.4 $ 0.5 $ — $ 238.9 Amortized Gross Gross Estimated At June 30, 2015: Cash and cash equivalents: Cash $ 54.7 $ — $ — $ 54.7 Cash equivalents 9.4 — — 9.4 Total cash and cash equivalents 64.1 — — 64.1 Available-for-sale: Corporate bonds and notes 41.8 — — 41.8 Municipal bonds 66.3 0.1 (0.1 ) 66.3 Federal agency issues 13.2 — — 13.2 US government securities — — — — Total $ 185.4 $ 0.1 $ (0.1 ) $ 185.4 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2016: Amortized Estimated Cash $ 66.1 $ 66.1 Cash equivalents 2.4 2.4 Available-for-sale: Due within one year 90.5 90.5 Due after one year through five years 79.4 79.9 Due after five years — — Total $ 238.4 $ 238.9 Debt securities in an unrealized loss position as of June 30, 2016 were not impaired at acquisition and the declines in fair value are not attributed to declines in credit quality. Management believes that it is more likely than not that the securities will be held until a recovery of par value. All securities in an unrealized loss position as of June 30, 2016 and 2015 are debt securities. Debt securities available-for-sale in a gross unrealized loss position as of June 30, 2016 and 2015 are summarized as follows: Less than 12 months More than 12 months Total Fair Unrealized Fair Unrealized Fair Unrealized losses At June 30, 2016: Debt securities: Corporate bonds and notes 5.0 — 1.5 — 6.5 — Municipal bonds 7.6 — 6.3 — 13.9 — Federal agency issues 6.0 — — — 6.0 — US government securities — — — — — — $ 18.6 $ — $ 7.8 $ — $ 26.4 $ — Less than 12 months More than 12 months Total Fair Unrealized Fair Unrealized Fair Unrealized At June 30, 2015: Debt securities: Corporate bonds and notes 24.4 (0.0 ) — — 24.4 (0.0 ) Municipal bonds 24.8 (0.1 ) — — 24.8 (0.1 ) Federal agency issues 1.9 (0.0 ) — — 1.9 (0.0 ) $ 51.1 $ (0.1 ) $ — $ — $ 51.1 $ (0.1 ) Additional information relating to fair value of marketable investment securities can be found in Note 12.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	4. PROPERTY, PLANT AND EQUIPMENT, NET Years Ended June 30, 2016 2015 Land $ 2.3 $ 2.3 Buildings and improvements 17.3 18.2 Leasehold improvements 18.7 18.5 Equipment 103.4 99.1 141.7 138.1 Less accumulated depreciation (83.4 ) (70.9 ) Property, plant and equipment, net $ 58.3 $ 67.2 Years Ended June 30, 2016 2015 2014 Depreciation expense $ 14.1 $ 12.3 $ 9.2

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. GOODWILL AND INTANGIBLE ASSETS Goodwill The Company has recorded goodwill of $195.3 from the acquisitions of Sividon Diagnostics that was completed on May 31, 2016, GmbH, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $129.9 relates to the Company’s diagnostic segment and $65.4 related to the other segment. The Company assessed goodwill for impairment in accordance with the appropriate guidance (see Note 1) and recorded no impairment of goodwill for the period ended June 30, 2016, 2015 and 2014. Included in the diagnostic segment is $17.7 in goodwill associated with the acquisition of Sividon which is preliminary and subject to adjustment within the measurement period (see Note 2). The following summarizes changes to the goodwill balance for the years ended June 30, 2016 and 2015: Years Ended June 30, 2016 2015 Beginning balance $ 177.2 $ 169.2 Acquisitions 17.7 8.1 Translation adjustments (0.2 ) (0.1 ) Measurement period adjustments (see note 2) 0.6 (0.1 ) Ending balance $ 195.3 $ 177.1 Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, developed technology, a laboratory database, trademarks, and customer relationships as well as non-amortizable intangible assets of in-process technologies, research and development. Certain of these intangible assets were recorded as part of the Company’s purchase of Sividon on March 31, 2016, Crescendo on February 28, 2014 and Myriad RBM on May 31, 2011. The Company’s developed technology and database acquired have estimated remaining useful lives between 16 and 20 years, trademarks acquired have an estimated remaining useful life of approximately 13 years and customer relationships have an estimated remaining useful life of approximately 6 years. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company concluded there was no impairment of long-lived assets for the years ended June 30, 2016, 2015 and 2014. The following summarizes the amounts reported as intangible assets: Gross Accumulated Net At June 30, 2016: Purchased licenses and technologies $ 228.7 $ (28.5 ) $ 200.2 Customer relationships 4.7 (2.4 ) 2.3 Trademarks 3.0 (0.6 ) 2.4 Total amortizable intangible assets 236.4 (31.5 ) 204.9 In-process research and development 22.6 — 22.6 Total unamortized intangible assets 22.6 — 22.6 Total intangible assets $ 259.0 $ (31.5 ) $ 227.5 Gross Accumulated Net At June 30, 2015: Purchased licenses and technologies $ 199.1 $ (16.7 ) $ 182.4 Customer relationships 4.7 (1.9 ) 2.8 Trademarks 3.0 (0.4 ) 2.6 Total amortizable intangible assets 206.8 (19.0 ) 187.8 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 211.6 $ (19.0 ) $ 192.6 As of June 30, 2016 the weighted average remaining amortization period for purchased licenses and technologies, trademarks, and customer relationships is approximately 15 years. The Company recorded amortization during the respective periods for these intangible assets as follows: Years Ended June 30, 2016 2015 2014 Amortization on intangible assets $ 12.6 $ 12.7 $ 4.6 Amortization expense of intangible assets is estimated to be $14.2 in 2017, $14.2 in 2018, $14.2 in 2019, $13.8 in 2020 and $13.8 in 2021 and $134.7 thereafter.

Cost Basis Investment

Cost Basis Investment	12 Months Ended
	Jun. 30, 2016
Investments, All Other Investments [Abstract]
Cost Basis Investment	6. COST BASIS INVESTMENT In April 2013, the Company acquired approximately 28 shares of Series E preferred stock of RainDance Technologies, Inc. (“RainDance”) of Lexington, Massachusetts, for $5.0. RainDance provides high-throughput picodroplet-based technology that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The Series E shares purchased by the Company represented less than 5% of the total shares outstanding of RainDance’s capital stock. Subsequent to the investment the Company evaluated its relationship with RainDance and determined it did not have significant influence over the operations of RainDance. The Company’s investment in RainDance has been recorded under the cost method as an “Other Asset” on the Company’s consolidated balance sheet. The Company periodically evaluates the investment for impairment. No impairment indicators were noted at June 30, 2016.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Liabilities	7. ACCRUED LIABILITIES Years Ended June 30, 2016 2015 Employee compensation and benefits $ 37.3 $ 33.8 Accrued taxes payable 2.8 3.8 Other 9.4 8.5 Total accrued liabilities $ 49.5 $ 46.1

Other Long Term Liabilities

Other Long Term Liabilities	12 Months Ended
	Jun. 30, 2016
Other Liabilities Disclosure [Abstract]
Other Long Term Liabilities	8. OTHER LONG TERM LIABILITIES Years Ended June 30, 2016 2015 Pension obligation $ 5.9 $ 4.9 Other 12.3 3.9 Total other long term liabilities $ 18.2 $ 8.8 The Company has two non-contributory defined benefit pension plans for its current and former Clinic employees. The Company has closed participation in the plans to exclude those employees hired after 2002. As of June 30, 2016 the fair value of the plan assets were approximately $0.1 resulting in a net pension liability of $5.9.

Preferred and Common Stockholde

Preferred and Common Stockholder's Equity	12 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Preferred and Common Stockholder's Equity	9. PREFERRED AND COMMON STOCKHOLDER’S EQUITY The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at June 30, 2016, 2015 and 2014. The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 69.1, 68.9, and 73.5 shares issued and outstanding at June 30, 2016, 2015 and 2014 respectively. Common shares issued and outstanding Years Ended June 30, 2016 2015 2014 Common stock issued and outstanding at July 1 68.9 73.5 80.6 Common stock issued upon exercise of options and employee stock plans 4.7 1.4 3.3 Repurchase and retirement of common stock (4.5 ) (6.0 ) (10.4 ) Common stock issued and outstanding at June 30 69.1 68.9 73.5 Stock Repurchase Program In June 2016, the Company’s Board of Directors authorized an eighth share repurchase program of $200.0 of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of June 30, 2016, the Company has $192.3 remaining on its current share repurchase authorization. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended June 30, 2016, 2015 and 2014 were as follows: Year ended June 30, 2016 2015 2014 Shares purchased and retired 4.5 6.0 10.4 Common stock and additional paid-in-capital reductions $ 41.2 $ 51.5 $ 82.5 Charges to retained earnings $ 121.4 $ 159.2 $ 205.1

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES Income tax expense consists of the following: Year ended June 30, 2016 2015 2014 Current: Federal $ 22.2 $ 53.7 $ 97.4 State 3.5 4.7 3.5 Total Current 25.7 58.4 100.9 Deferred: Federal 15.4 (2.1 ) (0.7 ) State (3.2 ) 8.7 0.8 Foreign 3.5 (2.3 ) (2.9 ) Change in valuation allowance 2.2 (8.0 ) 3.5 Total Deferred 17.9 (3.7 ) 0.7 Total income tax expense $ 43.6 $ 54.7 $ 101.6 Income (loss) before income taxes consists of the following: Year ended June 30, 2016 2015 2014 United States $ 169.5 $ 147.0 $ 292.0 Foreign (0.6 ) (12.1 ) (14.2 ) Total $ 168.9 $ 134.9 $ 277.8 The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of operations were as follows: Year ended June 30, 2016 2015 2014 Federal income tax expense at the statutory rate 35.0 % 35.0 % 35.0 % State income taxes, net of federal benefit 2.0 1.7 1.6 Research and development credits, net of the federal tax on state credits (1.3 ) (2.5 ) (0.2 ) Uncertain tax positions, net of federal benefit 0.6 1.2 (0.1 ) Uncertain tax benefits statute expired, net of federal benefit (4.4 ) 0.0 0.0 Incentive stock option and employee stock purchase plan expense (0.3 ) 0.2 (0.3 ) Adjustment to deferred tax liability attributable to acquired intangible assets 0.0 1.6 0.0 Foreign rate differential 0.0 1.6 0.8 Change in valuation allowance 1.2 2.6 1.2 Basis difference, disposition of foreign subsidiary 0.0 0.0 (1.9 ) California basis step-up election, net of related valuation allowance impact 0.0 (1.2 ) 0.0 Early adoption of ASU 2016-09 (7.5 ) 0.0 0.0 Other, net 0.5 0.4 0.5 25.8 % 40.6 % 36.6 The Company’s effective tax rate for the year ended June 30, 2016 was lower than the years ended June 30, 2015 and 2013. This decrease was primarily due the early adoption of ASU 2016-09 regarding stock compensation and a decrease in the Company’s liability for unrecognized tax benefits mainly due to a lapse of statute of limitations. Pursuant to the guidelines of the recently issued ASU 2015-17 (“the Update”), all deferred tax assets and liabilities are to be classified as non-current. The effective date of the Update for public companies is for annual periods beginning after December 15, 2016 and later dates for all other entities. Early adoption is permitted. To comply with the guidance, the Company elected to adopt this Update for the quarter ended December 31, 2015 and the annual period ending June 30, 2016. The guidance indicates that the Update may be applied either prospectively or retrospectively. The Company chose to apply the Update prospectively. Accordingly, no prior periods were adjusted. Upon adoption during the quarter ended December 31, 2015, approximately $13.5 of net current deferred tax assets were reclassified to non-current and netted against non-current deferred tax liabilities. At June 30, 2016, approximately $12.7 of what were formerly recorded as current deferred tax assets were reclassified to non-current and netted against non-current deferred tax liabilities. The FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, on March 30, 2016, in an effort to simplify the accounting for income taxes surrounding excess tax benefits. The Company elected early adoption in the fourth quarter of the current fiscal year. The guidance indicates that the provision is to be adopted prospectively and that any adjustment for the period ending June 30, 2016 must be reflected as of the beginning of the fiscal year. These adjustments have been reflected as required in both the effective tax rate table above, and the deferred tax asset and liabilities table below. The Company has made an entity-wide accounting policy election to continue to estimate the number of awards that are expected to vest and adjusting the estimate when it is likely to change. The significant components of the Company’s deferred tax assets and liabilities were comprised of the following at June 30, 2016 and 2015: Year ended June 30, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 54.4 $ 61.1 Property, plant and equipment 1.8 2.9 Accrued vacation 2.0 1.7 Allowance for doubtful accounts 2.4 2.7 Stock compensation expense 27.0 36.8 Research and development credits 9.4 8.9 Uncertain state tax positions 1.1 1.1 Other, net 0.7 0.9 Total gross deferred tax assets 98.8 116.1 Less valuation allowance (35.6 ) (33.4 ) Total deferred tax assets 63.2 82.7 Deferred tax liabilities: Intangible assets 81.1 69.4 Total deferred tax liabilities 81.1 69.4 Net deferred tax assets (liability) (17.9 ) 13.3 Current net deferred tax asset 0.0 13.5 Long term net deferred tax asset (liability) (17.9 ) (0.2 ) Net deferred tax asset (liability) $ (17.9 ) $ 13.3 Due to sustained positive operating performance and the availability of expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets, a valuation allowance has been established. For the years ended June 30, 2016 and 2015, the Company’s valuation allowance increased by $2.2 and decreased by $8.0, respectively. The net increase of the valuation allowance in the year ended June 30, 2016 consisted of an increase of $3.8 related to the early adoption of ASU 2016-09 with regard to state excess tax benefits, an increase of $1.9 related to additional state research credit carry-forwards, for which the company concluded it was more likely than not that the benefits of the losses and credits will not be realized. In addition, there was an offsetting decrease in the valuation allowance on foreign net operating losses in the amount of $3.5 which related to a corresponding decrease in the foreign net operating losses. The net decrease of the valuation allowance in the year ended June 30, 2015 consisted of a decrease of $11.5 related to the use of California net operating losses and credits made available through a post-acquisition California stand-alone state tax election and an offsetting increase in the amount of $3.5 which was related to foreign net operating losses and state tax research credits, for which the company concluded it was more likely than not that the benefits of the losses and credits will not be realized. The Company acquired Sividon Diagnostics GmbH on May 31, 2016 (see Note 2). As part of the purchase accounting for this acquisition a net deferred tax liability of approximately $13.2 was recorded, consisting primarily of intangible assets for which the book basis exceeds the tax basis. For the years ended June 30, 2016 and 2015, the Company realized $12.7 and $3.4, respectively, of excess tax benefits from stock-based compensation as a reduction of taxes payable. Company previously had adopted the with-and-without tax allocation approach for excess tax benefits, which results in the windfall tax benefits being utilized last after considering all other tax attributes available to the Company. Prior to the adoption of ASU 2016-09, excess tax benefits from stock based compensation were credited directly to additional paid-in-capital. The With the early adoption of ASU 2016-09, all excess tax benefits and tax deficiencies are recognized as income tax expense or benefit in the income statement. At June 30, 2016, the Company had the following net operating loss and research credit carryforwards, with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated. Carryforwards Amount Subject to Expires Through Federal net operating loss $ 112.3 Yes 2027 2033 Utah net operating loss 209.5 No 2016 2024 Oklahoma net operating loss 14.1 Yes 2023 2033 Foreign net operating losses (various jurisdictions) 30.1 No Various Various Federal research credit 3.2 Yes 2025 2032 Utah research credit 9.5 No 2021 2029 Due to a post-acquisition California stand-alone state election related to the acquisition of Crescendo Bioscience, Inc., all of Crescendo’s California net operating loss carryforwards and California research credit carryforwards were utilized or lost at the acquisition, resulting in no remaining carryforwards. All of the Utah net operating loss carryforwards are ‘excess tax benefits’ as defined by ASC guidance and, if realized in future years, will be recognized as a credit to tax benefit, pursuant to the guidance of ASU 2016-09 which was adopted during this fiscal year. The Company’s deferred tax asset for the Utah net operating loss ‘excess tax benefits’ is approximately $6.8 and is offset by a full valuation allowance at June 30, 2016. Consistent with the indefinite reversal criteria of ASC 740-30-25-17, the Company intends to invest undistributed earnings of its foreign subsidiaries indefinitely. Due to the cumulative losses that have been incurred to date in its foreign operations, the amount of unrecorded deferred liability resulting from the indefinite reversal criteria at June 30, 2016 is $0. In July 2006, the FASB issued ASC Topic 740 Subtopic 10 Section 05, which clarifies the accounting for uncertainty in tax positions. Accounting guidance requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company adopted the guidance on July 1, 2007 and recorded $0 cumulative effect. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year ended June 30, 2016 2015 2014 Unrecognized tax benefits at the beginning of year $ 26.3 $ 24.2 $ 10.9 Gross increases—current year tax positions 0.6 1.1 1.8 Gross increases—prior year tax positions 5.4 1.0 0.3 Gross increases—acquisitions — — 14.2 Gross decreases—prior year tax positions (8.1 ) — (3.0 ) Unrecognized tax benefits at end of year $ 24.2 $ 26.3 $ 24.2 Interest and penalties in year-end balance $ 0.5 $ 0.6 $ 0.3 Interest and penalties related to uncertain tax positions are included as a component of income tax expense. The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The years ended June 30, 2013 through June 30, 2016 remain subject to examination at June 30, 2016. The Company’s income tax returns for the following jurisdictions are currently under examination: New Jersey State income tax returns for the years ended June 30, 2007 through 2013; New York State income tax return for the years ended June 30, 2014 through 2015; and U.S. income tax return for the year June 30, 2014. Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued. The Company’s foreign income tax returns and all other state tax returns are not currently under examination.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	11. SHARE-BASED COMPENSATION The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 5, 2013, the shareholders approved an amendment to the 2010 Plan to set the number of shares available for grant to 3.5. As of June 30, 2016, a total of 2.3 shares of common stock are available for issuance under the 2010 Plan. In addition, as of June 30, 2016, the Company may grant up to 2.5 additional shares under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire in the future without the issuance of shares of common stock by the Company. The exercise price of options granted in 2016, 2015 and 2014 was equivalent to the fair market value of the stock at the date of grant. The number of shares, terms, and vesting periods are determined by the Company’s board of directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs generally vest ratably over four years on the anniversary date of the grant to all employees. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and restricted stock units granted to our non-employee directors vest in full upon the earlier of (i) one full year of service on the Board following date of grant or (ii) the date of the next annual meeting of stockholders. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for grants for the fiscal year ended June 30: 2014 Risk-free interest rate 1.6 % Expected dividend yield 0 % Expected lives (in years) 4.1 - 4.7 Expected volatility 40 % Expected option lives and volatilities are based on historical data of the Company and other factors. Stock Options A summary of option activity is as follows for the fiscal years ended June 30: 2016 2015 2014 Number Weighted Number Weighted Number Weighted Options outstanding at beginning of year 12.5 $ 23.49 14.2 $ 23.30 14.4 $ 21.75 Options granted — $ — — $ — 3.3 $ 26.52 Less: Options exercised (4.3 ) $ 21.51 (1.2 ) $ 20.17 (3.1 ) $ 19.44 Options canceled or expired — $ 0.00 (0.5 ) $ 25.98 (0.4 ) $ 24.30 Options outstanding at end of year 8.2 $ 24.52 12.5 $ 23.49 14.2 $ 23.30 Options exercisable at end of year 6.7 $ 24.04 9.6 $ 22.80 7.1 $ 21.90 Options vested and expected to vest 8.2 $ 24.52 12.5 $ 23.49 13.4 $ 23.12 Weighted average fair value of options granted during the year $ — $ — $ 10.04 The following table summarizes information about stock options outstanding at June 30, 2016: Options outstanding Options exercisable Range of exercise prices Number at June 30, 2016 Weighted average remaining life (years) Weighted average exercise price Number at June 30, 2016 Weighted average exercise price $9.04 - 21.29 2.1 4.55 $ 18.25 2.1 $ 18.25 21.66 - 26.49 3.3 4.71 25.32 2.3 24.80 26.84 - 30.12 2.2 5.39 27.83 1.8 27.98 $30.34 - 37.73 0.6 3.26 30.46 0.5 30.40 8.2 4.76 $ 24.52 6.7 $ 24.04 Options exercisable at June 30, 2016 had a weighted average remaining contractual life of 4.6 years. As of June 30, 2016, there was $6.5 of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 0.9 years. Restricted Stock Units A summary of RSU activity is as follows: 2016 2015 Number Weighted Number Weighted RSUs outstanding at the beginning of year 1.0 $ 37.63 — $ — RSUs granted 0.8 40.62 1.2 37.66 Less: RSUs released (0.4 ) 39.74 — 34.22 RSUs canceled — — (0.2 ) 38.12 RSUs outstanding at end of year 1.4 $ 38.76 1.0 $ 37.63 As of June 30, 2016, there was $30.9 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.3 years. Share-based compensation expense recognized and included in the consolidated statements of operations for the fiscal years ended June 30, 2016, 2015 and 2014 was as follows: Years Ended June 30, 2016 2015 2014 Cost of molecular diagnostic testing $ 0.9 $ 0.9 $ 0.8 Cost of pharmaceutical and clinical services 0.4 0.5 0.3 Research and development expense 5.4 4.3 5.4 Selling, general, and administrative expense 24.9 40.0 27.5 Total share-based compensation expense $ 31.6 $ 45.7 $ 34.0 In October 2014, the Company and its former Chief Financial Officer entered into a resignation agreement under which the vesting of certain awards were modified such that the specified awards were vested in full. As a result of this award modification the Company recognized approximately $3.1 in share-based compensation expense for year ended June 30, 2015. In February 2015, the Company and its former Chief Executive Officer entered into a resignation agreement under which the vesting of certain awards were modified such that the specified awards were accelerated. As a result of this award modification the Company recognized approximately $12.8 in share-based compensation expense for year ended June 30, 2015. The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: As of Unrecognized share-based compensation cost $ 38.2 Aggregate intrinsic value of options outstanding 49.6 Aggregate intrinsic value of options fully vested 43.9 Aggregate intrinsic value of RSUs outstanding $ 43.5 The total intrinsic value of options exercised during 2016, 2015 and 2014 was as follows: Years Ended June 30, 2016 2015 2014 Total intrinsic value of options exercised $ 86.1 $ 20.5 $ 49.4 Employee Stock Purchase Plan The Company had an Employee Stock Purchase Plan that was approved by shareholders in 1995 (the “1995 Purchase Plan”), and subsequently amended, under which 2.0 shares of common stock had been authorized. As of December 5, 2012, a total of 2.0 shares of common stock had been issued under the 1995 Purchase Plan when it was terminated. On December 5, 2012, following shareholder approval, the Company adopted the 2012 Employee Stock Purchase Plan (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At June 30, 2016, a total of 0.7 shares of common stock had been purchased under the 2012 Plan. Shares purchased under and compensation expense associated with the 1995 and 2012 Plans for the years reported are as follows: Years Ended June 30, 2016 2015 2014 Shares purchased under the plans 0.2 0.2 0.2 Plan compensation expense $ 1.9 $ 1.8 $ 1.3 As of June 30, 2016, there was $0.8 of total unrecognized share-based compensation expense related to ESPP. The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black-Scholes option-pricing model using the following weighted-average assumptions: 2016 2015 2014 Risk-free interest rate 0.4 % 0.1 % 0.1 % Expected dividend yield 0 % 0 % 0 % Expected lives (in years) 0.5 0.5 0.5 Expected volatility 31 % 33 % 56 %

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. The substantial majority of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. The following table sets forth the fair value of the Company’s financial assets that are re-measured on a regular basis: Level 1 Level 2 Level 3 Total June 30, 2016 Money market funds (a) $ 2.4 $ — $ — $ 2.4 Corporate bonds and notes — 51.0 — 51.0 Municipal bonds — 85.6 — 85.6 Federal agency issues — 25.5 — 25.5 US government securities — 8.3 — 8.3 Total $ 2.4 $ 170.4 $ — $ 172.8 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest Level 1 Level 2 Level 3 Total June 30, 2015 Money market funds (a) $ 2.4 $ — $ — $ 2.4 Corporate bonds and notes — 44.8 — 44.8 Municipal bonds — 70.3 — 70.3 Federal agency issues — 13.2 — 13.2 Total $ 2.4 $ 128.3 $ — $ 130.7 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest The Company’s Level 1 assets include money market instruments. Level 2 assets consist of marketable investment securities that include federal agency issues, commercial paper, corporate bonds, US government securities and municipal bonds. Level 2 securities are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. As of June 30, 2016 and 2015, the Company had no investments which were measured using unobservable (Level 3) inputs.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	13. COMMITMENT AND CONTINGENCIES The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2016, management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows. As of June 30, 2016, Crescendo Bioscience, Inc. has approximately two months remaining under an unconditional purchase obligation with a vendor to purchase goods and services used in the Company’s diagnostic processes. The agreement specifies certain minimum quantities and pricing terms. As of June 30, 2016 under this agreement the Company has expended as follows: Amount Fiscal year ending: 2014 $ 10.4 2015 10.9 2016 27.3 Total expended on unconditional purchase obligations $ 48.6 In addition to the minimum quantities and pricing terms, the Company may also make additional purchase commitments of anticipated purchases based upon forecasted needs which are not included in the unconditional purchase obligation amounts below. As of June 30, 2016, the remaining obligations under this agreement were as follows: Amount Fiscal year ending: 2017 $ 6.1 Total commitment for unconditional purchase obligations $ 6.1 The Company leases office and laboratory space under five non-cancelable operating leases, with terms that expire between 2022 and 2027 in Salt Lake City, Utah, one cancelable lease for office and laboratory space with a term that expires in 2018 in Munich, Germany, a non-cancelable operating lease for Myriad RBM for office and laboratory space that expires in 2020 in Austin, Texas, and a non-cancelable lease for office and laboratory space that expires in 2017 in Colgne, Germany. The Company also leases office and laboratory space under one non-cancellable operating lease that expires in 2017 in South San Francisco, California for Crescendo. In addition, the Company maintains lease agreements that expire between 2015 and 2020 for administrative offices in Zurich, Switzerland; Paris, France; Madrid, Spain; Milan, Italy; London, UK and Munich, Germany. Furthermore, the Company leases information technology equipment under four non-cancelable leases, with terms that expire in 2018 and 2019. The following is a summary of the Company’s rental expense for the fiscal years reported: Years Ended June 30, 2016 2015 2014 Rental expense $ 14.3 $ 13.8 $ 11.3 Future minimum lease payments under the Company’s current leases as of June 30, 2016 are as follows: Fiscal year ending: 2017 $ 12.9 2018 12.6 2019 12.1 2020 12.4 2021 10.6 Thereafter 41.3 $ 101.9

Employee Deferred Savings Plan

Employee Deferred Savings Plan	12 Months Ended
	Jun. 30, 2016
Postemployment Benefits [Abstract]
Employee Deferred Savings Plan	14. EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company’s recorded contributions to the plan as follows: Years Ended June 30, 2016 2015 2014 Deferred savings plan Company contributions $ 5.5 $ 5.1 $ 4.4

Segment and Related Information

Segment and Related Information	12 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segment and Related Information	15. SEGMENT AND RELATED INFORMATION The Company’s business units have been changed to align with how its Chief Operating Decision Maker (“CODM”) reviews performance and makes decisions in managing the Company. The business units were historically comprised of three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services. Beginning in fiscal 2015 the business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other, which was formerly the research and pharmaceutical and clinical services segments. The diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Prior periods presented have been recast to conform to the current presentation. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense. Diagnostics Other Total Year ended June 30, 2016: Revenues $ 705.7 $ 48.1 $ 753.8 Depreciation and amortization 21.5 5.2 26.7 Segment operating income (loss) 239.3 (72.5 ) 166.8 Year ended June 30, 2015: Revenues $ 695.5 $ 27.6 $ 723.1 Depreciation and amortization 20.5 4.5 25.0 Segment operating income (loss) 217.1 (82.9 ) 134.2 Year ended June 30, 2014: Revenues $ 748.2 $ 30.0 $ 778.2 Depreciation and amortization 9.9 3.9 13.8 Segment operating income (loss) 338.0 (63.6 ) 274.4 Years Ended June 30, 2016 2015 2014 Total operating income for reportable segments $ 166.8 $ 134.2 $ 274.4 Unallocated amounts: Interest income 0.9 0.4 5.4 Other 1.2 0.3 (2.0 ) Income from operations before income taxes 168.9 134.9 277.8 Income tax provision 43.6 54.7 101.6 Net income $ 125.3 $ 80.2 $ 176.2 The following table sets forth a comparison of balance sheet assets by operating segment: June 30, 2016 2015 Net equipment, leasehold improvements and property: Diagnostics 26.3 34.5 Other 32.0 32.7 Total $ 58.3 $ 67.2 Total Assets: Diagnostics 512.4 450.6 Other 129.2 130.2 Total $ 641.6 $ 580.8 The following table reconciles assets by geographical region: June 30, 2016 2015 Net equipment, leasehold improvements and property: United States 33.6 42.2 Rest of world 24.7 25.0 Total $ 58.3 $ 67.2 Total Assets: United States 532.6 537.3 Rest of world 109.0 43.5 Total $ 641.6 $ 580.8 The following table reconciles assets by operating segment and geographic region to total assets: June 30, 2015 2015 Total assets by segment and geographical region $ 641.6 $ 580.8 Cash, cash equivalents, and marketable investment securities (1) 238.9 185.4 Total $ 880.5 $ 766.2 (1) The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments The majority of the Company’s revenues were derived from the sale of diagnostic tests in the United States. There were no customers that accounted for greater than 10% of revenue in the years ended June 30, 2016, 2015 and 2014.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Jun. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	16. SUPPLEMENTAL CASH FLOW INFORMATION Years Ended June 30, 2016 2015 2014 Cash paid during the year for income taxes $ 32.0 $ 39.1 $ 108.2 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to stockholders’ equity 0.3 — (0.4 )

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	17. SUBSEQUENT EVENTS On August 3, 2016, Myriad Genetics, Inc. (“Myriad”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Myriad Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Subsidiary”), Assurex Health, Inc. (“Assurex”), and Fortis Advisors LLC, as the representative of the securityholders of Assurex. The Merger Agreement provides that Myriad will pay an aggregate cash purchase price to the security holders of Assurex of $225 million, subject to adjustment for Assurex’s working capital and indebtedness and other amounts to be determined in accordance with the Merger Agreement (as adjusted, the “Purchase Price”). Additionally, subject to the limitations described in the Merger Agreement , Myriad will be required to pay securityholders additional amounts in cash of up to $185 million in performance-based milestones (the “Additional Payments,” and together with the Purchase Price, the “Merger Consideration”). The acquisition is structured as a reverse triangular merger transaction in which the Merger Subsidiary will merge with and into Assurex, with Assurex surviving the merger as the surviving corporation and a wholly owned subsidiary of Myriad (the “Merger”). The Merger Agreement contains certain termination rights for Myriad and Assurex, including the right by either party to terminate the Merger Agreement if the Merger has not occurred within two months of the signing of the Merger Agreement. The Closing is expected to occur before the end of the first quarter of Myriad’s fiscal year 2017, and is subject to customary closing conditions and regulatory approval including, among others, antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Myriad intends to fund the transaction through cash on hand and possibly short-term debt. The acquisition is not subject to a financing contingency. The Merger Agreement was approved by the Board of Directors of both Myriad and Assurex, and is conditioned on receiving the requisite stockholder approval of the Assurex stockholders.

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Jun. 30, 2016
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts	MYRIAD GENETICS, INC. Schedule of Valuation and Qualifying Accounts Years Ended June 30, 2016, 2015, and 2014 (In millions) Balance at Addition Net Deductions Balance at Allowance for doubtful accounts: Year ended June 30, 2016 $ 7.6 $ 33.3 ($ 34.1 ) $ 6.8 Year ended June 30, 2015 $ 9.0 $ 31.5 ($ 32.9 ) $ 7.6 Year ended June 30, 2014 $ 7.5 $ 39.2 ($ 37.7 ) $ 9.0 (1) Primarily represents the write-off of accounts receivables net of recoveries.

Organization and Summary of S26

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine tests. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company generates revenue by performing molecular diagnostic tests as well as by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah. The consolidated financial statements of the Company are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP. Certain reclassifications have been made to prior period amounts to conform to the current period presentation. A reclassification of $0.6 from proceeds from maturities and sales of marketable securities was made to reflect the effect of foreign exchange rates on cash and cash equivalents in the condensed consolidated statement of cash flows and for the fiscal year ended June 30, 2014 and a reclassification of $0.6 from other receivables to trade accounts receivable in the condensed consolidated balance sheet for fiscal year ended June 30, 2014 to conform to the current-year presentation.
Marketable Investment Securities	Marketable Investment Securities The Company has classified its marketable investment securities as available-for-sale. Available-for-sale investment securities with remaining maturities of greater than one year are classified as long-term. Available-for-sale investment securities with remaining maturities of one year or less are classified as short-term. Available-for-sale investment securities with remaining maturities of less than three months at the time of purchase are classified as cash equivalents. Marketable securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported using the specific-identification method. Dividend and interest income are recognized when earned. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. We review several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) our ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the fiscal years ended June 30, 2016, 2015 and 2014.
Inventory	Inventory Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers.
Trade Accounts Receivable and Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are comprised of amounts due from sales of the Company’s molecular diagnostic tests and pharmaceutical and clinical services and are recorded at the invoiced amount, net of discounts and contractual allowances. The allowance for doubtful accounts is based on the Company’s best estimate of the amount of probable losses in the Company’s existing accounts receivable, which is based on historical write-off experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
Property, Plant and Equipment	Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to fifteen years. Repairs and maintenance costs are charged to expense as incurred.
Intangible Assets and Other Long-Lived Assets	Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses, technology and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill Goodwill is tested for impairment on an annual basis as of April 1 and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill was first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a two-step impairment analysis is performed. The first step involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the second step of the process involves a comparison of the fair value and the carrying amount of the goodwill of that reporting unit. If the carrying amount of the goodwill of the reporting unit exceeds the fair value of that goodwill, an impairment loss would be recognized in an amount equal to the excess of carrying value over fair value. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
Revenue Recognition	Revenue Recognition Molecular diagnostic testing revenue is recognized when persuasive evidence of an agreement exists, results have been communicated to the patient, the fee is fixed or determinable, and collection is reasonably assured. Revenue from the sale of molecular diagnostic tests and related marketing agreements is recorded at the invoiced amount net of any discounts or contractual allowances. Pharmaceutical and clinical service revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed and or determinable, when the service has been completed and the results of the tests/service are provided to the customer, and collectability is reasonably assured. In addition, the Company’s wholly owned subsidiary, Myriad RBM, has received national, state, foreign government and private foundation grants and contracts. Revenue associated with these grants and contracts is recognized in the period in which qualifying costs for the services by the grants and contracts are incurred and the related grant or contract fee is earned.
Income Taxes	Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2016 2015 2014 Denominator: Weighted-average shares outstanding used to compute basic EPS 70.0 71.3 75.7 Effect of dilutive stock options 3.4 3.2 2.5 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 73.4 74.5 78.2 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2016 2015 2014 Anti-dilutive options and RSUs excluded from EPS computation — — —
Foreign Currency	Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ (deficit) equity. The following table shows the cumulative translation adjustments included in other comprehensive income: Balance at June 30, 2015 $ (7.0 ) Period translation adjustments (2.6 ) Ending balance June 30, 2016 (9.6 )
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation—Stock Compensation (Topic 718) (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. ASU 2016-09 will be effective for the Company beginning in its first quarter of 2018. We adopted this guidance during the current quarter. For discussion of impact see note 10 to the financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its first quarter of 2020 and early adoption is permitted. We are currently evaluating the timing of its adoption and the impact of adopting the new lease standard on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, which requires all deferred tax assets and liabilities to be classified as non-current. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016. Early adoption is permitted. We adopted this guidance in the current fiscal year. Refer to note 10 for discussion on the impact of adoption. In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, “Revenue from Contracts with Customers.” Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. In July 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Organization and Summary of S27

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2016 2015 2014 Denominator: Weighted-average shares outstanding used to compute basic EPS 70.0 71.3 75.7 Effect of dilutive stock options 3.4 3.2 2.5 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 73.4 74.5 78.2
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2016 2015 2014 Anti-dilutive options and RSUs excluded from EPS computation — — —
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Schedule of Cumulative Translation Adjustments Included in Other Comprehensive Income	The following table shows the cumulative translation adjustments included in other comprehensive income: Balance at June 30, 2015 $ (7.0 ) Period translation adjustments (2.6 ) Ending balance June 30, 2016 (9.6 )

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2016
Sividon Diagnostics GmbH
Allocation of Consideration Transferred	The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). Estimated Fair Current assets $ 2.7 Intangible assets 46.2 Equipment 0.3 Goodwill 17.7 Current liabilites (15.4 ) Total fair value purchase price $ 51.5 Less: Contingent consideration (10.5 ) Less: Cash acquired (2.0 ) Total cash consideration transferred $ 39.0
German Clinic [Member]
Allocation of Consideration Transferred	Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. This acquisition accounting is now final. Fair Value Current assets $ 3.1 Real property 20.7 Equipment 1.6 Goodwill 8.7 Current liabilites (4.4 ) Long-term liabilities (9.6 ) Total purchase price $ 20.1

Marketable Investment Securit29

Marketable Investment Securities (Tables)	12 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2016 and 2015 were as follows: Amortized Gross Gross Estimated At June 30, 2016: Cash and cash equivalents: Cash $ 66.1 $ — $ — $ 66.1 Cash equivalents 2.4 — — 2.4 Total cash and cash equivalents 68.5 — — 68.5 Available-for-sale: Corporate bonds and notes 50.8 0.2 — 51.0 Municipal bonds 85.4 0.2 — 85.6 Federal agency issues 25.5 — — 25.5 US government securities 8.2 0.1 — 8.3 Total $ 238.4 $ 0.5 $ — $ 238.9 Amortized Gross Gross Estimated At June 30, 2015: Cash and cash equivalents: Cash $ 54.7 $ — $ — $ 54.7 Cash equivalents 9.4 — — 9.4 Total cash and cash equivalents 64.1 — — 64.1 Available-for-sale: Corporate bonds and notes 41.8 — — 41.8 Municipal bonds 66.3 0.1 (0.1 ) 66.3 Federal agency issues 13.2 — — 13.2 US government securities — — — — Total $ 185.4 $ 0.1 $ (0.1 ) $ 185.4
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2016: Amortized Estimated Cash $ 66.1 $ 66.1 Cash equivalents 2.4 2.4 Available-for-sale: Due within one year 90.5 90.5 Due after one year through five years 79.4 79.9 Due after five years — — Total $ 238.4 $ 238.9
Schedule of Debt Securities Available-For-Sale in Gross Unrealized Loss Position	Debt securities available-for-sale in a gross unrealized loss position as of June 30, 2016 and 2015 are summarized as follows: Less than 12 months More than 12 months Total Fair Unrealized Fair Unrealized Fair Unrealized losses At June 30, 2016: Debt securities: Corporate bonds and notes 5.0 — 1.5 — 6.5 — Municipal bonds 7.6 — 6.3 — 13.9 — Federal agency issues 6.0 — — — 6.0 — US government securities — — — — — — $ 18.6 $ — $ 7.8 $ — $ 26.4 $ — Less than 12 months More than 12 months Total Fair Unrealized Fair Unrealized Fair Unrealized At June 30, 2015: Debt securities: Corporate bonds and notes 24.4 (0.0 ) — — 24.4 (0.0 ) Municipal bonds 24.8 (0.1 ) — — 24.8 (0.1 ) Federal agency issues 1.9 (0.0 ) — — 1.9 (0.0 ) $ 51.1 $ (0.1 ) $ — $ — $ 51.1 $ (0.1 )

Property, Plant and Equipment30

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Years Ended June 30, 2016 2015 Land $ 2.3 $ 2.3 Buildings and improvements 17.3 18.2 Leasehold improvements 18.7 18.5 Equipment 103.4 99.1 141.7 138.1 Less accumulated depreciation (83.4 ) (70.9 ) Property, plant and equipment, net $ 58.3 $ 67.2 Years Ended June 30, 2016 2015 2014 Depreciation expense $ 14.1 $ 12.3 $ 9.2

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following summarizes changes to the goodwill balance for the years ended June 30, 2016 and 2015: Years Ended June 30, 2016 2015 Beginning balance $ 177.2 $ 169.2 Acquisitions 17.7 8.1 Translation adjustments (0.2 ) (0.1 ) Measurement period adjustments (see note 2) 0.6 (0.1 ) Ending balance $ 195.3 $ 177.1
Summarized Amounts Reported as Intangible Assets	The following summarizes the amounts reported as intangible assets: Gross Accumulated Net At June 30, 2016: Purchased licenses and technologies $ 228.7 $ (28.5 ) $ 200.2 Customer relationships 4.7 (2.4 ) 2.3 Trademarks 3.0 (0.6 ) 2.4 Total amortizable intangible assets 236.4 (31.5 ) 204.9 In-process research and development 22.6 — 22.6 Total unamortized intangible assets 22.6 — 22.6 Total intangible assets $ 259.0 $ (31.5 ) $ 227.5 Gross Accumulated Net At June 30, 2015: Purchased licenses and technologies $ 199.1 $ (16.7 ) $ 182.4 Customer relationships 4.7 (1.9 ) 2.8 Trademarks 3.0 (0.4 ) 2.6 Total amortizable intangible assets 206.8 (19.0 ) 187.8 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 211.6 $ (19.0 ) $ 192.6
Amortization for Intangible Assets	The Company recorded amortization during the respective periods for these intangible assets as follows: Years Ended June 30, 2016 2015 2014 Amortization on intangible assets $ 12.6 $ 12.7 $ 4.6

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Summary of Accrued Liabilities	Years Ended June 30, 2016 2015 Employee compensation and benefits $ 37.3 $ 33.8 Accrued taxes payable 2.8 3.8 Other 9.4 8.5 Total accrued liabilities $ 49.5 $ 46.1

Other Long Term Liabilities (Ta

Other Long Term Liabilities (Tables)	12 Months Ended
	Jun. 30, 2016
Other Liabilities Disclosure [Abstract]
Summary of Other Long Term Liabilities	Years Ended June 30, 2016 2015 Pension obligation $ 5.9 $ 4.9 Other 12.3 3.9 Total other long term liabilities $ 18.2 $ 8.8

Preferred and Common Stockhol34

Preferred and Common Stockholder's Equity (Tables)	12 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Common Shares Issued and Outstanding	Common shares issued and outstanding Years Ended June 30, 2016 2015 2014 Common stock issued and outstanding at July 1 68.9 73.5 80.6 Common stock issued upon exercise of options and employee stock plans 4.7 1.4 3.3 Repurchase and retirement of common stock (4.5 ) (6.0 ) (10.4 ) Common stock issued and outstanding at June 30 69.1 68.9 73.5
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended June 30, 2016, 2015 and 2014 were as follows: Year ended June 30, 2016 2015 2014 Shares purchased and retired 4.5 6.0 10.4 Common stock and additional paid-in-capital reductions $ 41.2 $ 51.5 $ 82.5 Charges to retained earnings $ 121.4 $ 159.2 $ 205.1

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Schedule of Income Tax Expense	Income tax expense consists of the following: Year ended June 30, 2016 2015 2014 Current: Federal $ 22.2 $ 53.7 $ 97.4 State 3.5 4.7 3.5 Total Current 25.7 58.4 100.9 Deferred: Federal 15.4 (2.1 ) (0.7 ) State (3.2 ) 8.7 0.8 Foreign 3.5 (2.3 ) (2.9 ) Change in valuation allowance 2.2 (8.0 ) 3.5 Total Deferred 17.9 (3.7 ) 0.7 Total income tax expense $ 43.6 $ 54.7 $ 101.6
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consists of the following: Year ended June 30, 2016 2015 2014 United States $ 169.5 $ 147.0 $ 292.0 Foreign (0.6 ) (12.1 ) (14.2 ) Total $ 168.9 $ 134.9 $ 277.8
Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported in Consolidated Statements of Operations	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of operations were as follows: Year ended June 30, 2016 2015 2014 Federal income tax expense at the statutory rate 35.0 % 35.0 % 35.0 % State income taxes, net of federal benefit 2.0 1.7 1.6 Research and development credits, net of the federal tax on state credits (1.3 ) (2.5 ) (0.2 ) Uncertain tax positions, net of federal benefit 0.6 1.2 (0.1 ) Uncertain tax benefits statute expired, net of federal benefit (4.4 ) 0.0 0.0 Incentive stock option and employee stock purchase plan expense (0.3 ) 0.2 (0.3 ) Adjustment to deferred tax liability attributable to acquired intangible assets 0.0 1.6 0.0 Foreign rate differential 0.0 1.6 0.8 Change in valuation allowance 1.2 2.6 1.2 Basis difference, disposition of foreign subsidiary 0.0 0.0 (1.9 ) California basis step-up election, net of related valuation allowance impact 0.0 (1.2 ) 0.0 Early adoption of ASU 2016-09 (7.5 ) 0.0 0.0 Other, net 0.5 0.4 0.5 25.8 % 40.6 % 36.6
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following at June 30, 2016 and 2015: Year ended June 30, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 54.4 $ 61.1 Property, plant and equipment 1.8 2.9 Accrued vacation 2.0 1.7 Allowance for doubtful accounts 2.4 2.7 Stock compensation expense 27.0 36.8 Research and development credits 9.4 8.9 Uncertain state tax positions 1.1 1.1 Other, net 0.7 0.9 Total gross deferred tax assets 98.8 116.1 Less valuation allowance (35.6 ) (33.4 ) Total deferred tax assets 63.2 82.7 Deferred tax liabilities: Intangible assets 81.1 69.4 Total deferred tax liabilities 81.1 69.4 Net deferred tax assets (liability) (17.9 ) 13.3 Current net deferred tax asset 0.0 13.5 Long term net deferred tax asset (liability) (17.9 ) (0.2 ) Net deferred tax asset (liability) $ (17.9 ) $ 13.3
Summary of Net Operating Loss and Research Credit Carryforwards	At June 30, 2016, the Company had the following net operating loss and research credit carryforwards, with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated. Carryforwards Amount Subject to Expires Through Federal net operating loss $ 112.3 Yes 2027 2033 Utah net operating loss 209.5 No 2016 2024 Oklahoma net operating loss 14.1 Yes 2023 2033 Foreign net operating losses (various jurisdictions) 30.1 No Various Various Federal research credit 3.2 Yes 2025 2032 Utah research credit 9.5 No 2021 2029
Schedule of Reconciliation of Beginning and Ending Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year ended June 30, 2016 2015 2014 Unrecognized tax benefits at the beginning of year $ 26.3 $ 24.2 $ 10.9 Gross increases—current year tax positions 0.6 1.1 1.8 Gross increases—prior year tax positions 5.4 1.0 0.3 Gross increases—acquisitions — — 14.2 Gross decreases—prior year tax positions (8.1 ) — (3.0 ) Unrecognized tax benefits at end of year $ 24.2 $ 26.3 $ 24.2 Interest and penalties in year-end balance $ 0.5 $ 0.6 $ 0.3

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2016
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for grants for the fiscal year ended June 30: 2014 Risk-free interest rate 1.6 % Expected dividend yield 0 % Expected lives (in years) 4.1 - 4.7 Expected volatility 40 %
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	A summary of option activity is as follows for the fiscal years ended June 30: 2016 2015 2014 Number Weighted Number Weighted Number Weighted Options outstanding at beginning of year 12.5 $ 23.49 14.2 $ 23.30 14.4 $ 21.75 Options granted — $ — — $ — 3.3 $ 26.52 Less: Options exercised (4.3 ) $ 21.51 (1.2 ) $ 20.17 (3.1 ) $ 19.44 Options canceled or expired — $ 0.00 (0.5 ) $ 25.98 (0.4 ) $ 24.30 Options outstanding at end of year 8.2 $ 24.52 12.5 $ 23.49 14.2 $ 23.30 Options exercisable at end of year 6.7 $ 24.04 9.6 $ 22.80 7.1 $ 21.90 Options vested and expected to vest 8.2 $ 24.52 12.5 $ 23.49 13.4 $ 23.12 Weighted average fair value of options granted during the year $ — $ — $ 10.04
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Option Exercisable	The following table summarizes information about stock options outstanding at June 30, 2016: Options outstanding Options exercisable Range of exercise prices Number at June 30, 2016 Weighted average remaining life (years) Weighted average exercise price Number at June 30, 2016 Weighted average exercise price $9.04 - 21.29 2.1 4.55 $ 18.25 2.1 $ 18.25 21.66 - 26.49 3.3 4.71 25.32 2.3 24.80 26.84 - 30.12 2.2 5.39 27.83 1.8 27.98 $30.34 - 37.73 0.6 3.26 30.46 0.5 30.40 8.2 4.76 $ 24.52 6.7 $ 24.04
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding	A summary of RSU activity is as follows: 2016 2015 Number Weighted Number Weighted RSUs outstanding at the beginning of year 1.0 $ 37.63 — $ — RSUs granted 0.8 40.62 1.2 37.66 Less: RSUs released (0.4 ) 39.74 — 34.22 RSUs canceled — — (0.2 ) 38.12 RSUs outstanding at end of year 1.4 $ 38.76 1.0 $ 37.63
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations	Share-based compensation expense recognized and included in the consolidated statements of operations for the fiscal years ended June 30, 2016, 2015 and 2014 was as follows: Years Ended June 30, 2016 2015 2014 Cost of molecular diagnostic testing $ 0.9 $ 0.9 $ 0.8 Cost of pharmaceutical and clinical services 0.4 0.5 0.3 Research and development expense 5.4 4.3 5.4 Selling, general, and administrative expense 24.9 40.0 27.5 Total share-based compensation expense $ 31.6 $ 45.7 $ 34.0
Schedule of Unrecognized Share-Based Compensation Cost	The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: As of Unrecognized share-based compensation cost $ 38.2 Aggregate intrinsic value of options outstanding 49.6 Aggregate intrinsic value of options fully vested 43.9 Aggregate intrinsic value of RSUs outstanding $ 43.5
Schedule of Intrinsic Value of Options Exercised	The total intrinsic value of options exercised during 2016, 2015 and 2014 was as follows: Years Ended June 30, 2016 2015 2014 Total intrinsic value of options exercised $ 86.1 $ 20.5 $ 49.4
Schedule of Shares Purchased and Compensation Expenses	Shares purchased under and compensation expense associated with the 1995 and 2012 Plans for the years reported are as follows: Years Ended June 30, 2016 2015 2014 Shares purchased under the plans 0.2 0.2 0.2 Plan compensation expense $ 1.9 $ 1.8 $ 1.3
Employee Stock Purchase Plan
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions	The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black-Scholes option-pricing model using the following weighted-average assumptions: 2016 2015 2014 Risk-free interest rate 0.4 % 0.1 % 0.1 % Expected dividend yield 0 % 0 % 0 % Expected lives (in years) 0.5 0.5 0.5 Expected volatility 31 % 33 % 56 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets	The following table sets forth the fair value of the Company’s financial assets that are re-measured on a regular basis: Level 1 Level 2 Level 3 Total June 30, 2016 Money market funds (a) $ 2.4 $ — $ — $ 2.4 Corporate bonds and notes — 51.0 — 51.0 Municipal bonds — 85.6 — 85.6 Federal agency issues — 25.5 — 25.5 US government securities — 8.3 — 8.3 Total $ 2.4 $ 170.4 $ — $ 172.8 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest Level 1 Level 2 Level 3 Total June 30, 2015 Money market funds (a) $ 2.4 $ — $ — $ 2.4 Corporate bonds and notes — 44.8 — 44.8 Municipal bonds — 70.3 — 70.3 Federal agency issues — 13.2 — 13.2 Total $ 2.4 $ 128.3 $ — $ 130.7 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Summary of Expended Unconditional Purchase Obligation	As of June 30, 2016 under this agreement the Company has expended as follows: Amount Fiscal year ending: 2014 $ 10.4 2015 10.9 2016 27.3 Total expended on unconditional purchase obligations $ 48.6
Summary of Remaining Unconditional Purchase Obligation	As of June 30, 2016, the remaining obligations under this agreement were as follows: Amount Fiscal year ending: 2017 $ 6.1 Total commitment for unconditional purchase obligations $ 6.1
Summary of Rental Expense	The following is a summary of the Company’s rental expense for the fiscal years reported: Years Ended June 30, 2016 2015 2014 Rental expense $ 14.3 $ 13.8 $ 11.3
Future Minimum Lease Payments	Future minimum lease payments under the Company’s current leases as of June 30, 2016 are as follows: Fiscal year ending: 2017 $ 12.9 2018 12.6 2019 12.1 2020 12.4 2021 10.6 Thereafter 41.3 $ 101.9

Employee Deferred Savings Plan

Employee Deferred Savings Plan (Tables)	12 Months Ended
	Jun. 30, 2016
Postemployment Benefits [Abstract]
Recorded Contributions to Employee Deferred Savings Plan	The Company’s recorded contributions to the plan as follows: Years Ended June 30, 2016 2015 2014 Deferred savings plan Company contributions $ 5.5 $ 5.1 $ 4.4

Segment and Related Informati40

Segment and Related Information (Tables)	12 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense	The Company evaluates segment performance based on income (loss) before interest income and other income and expense. Diagnostics Other Total Year ended June 30, 2016: Revenues $ 705.7 $ 48.1 $ 753.8 Depreciation and amortization 21.5 5.2 26.7 Segment operating income (loss) 239.3 (72.5 ) 166.8 Year ended June 30, 2015: Revenues $ 695.5 $ 27.6 $ 723.1 Depreciation and amortization 20.5 4.5 25.0 Segment operating income (loss) 217.1 (82.9 ) 134.2 Year ended June 30, 2014: Revenues $ 748.2 $ 30.0 $ 778.2 Depreciation and amortization 9.9 3.9 13.8 Segment operating income (loss) 338.0 (63.6 ) 274.4 Years Ended June 30, 2016 2015 2014 Total operating income for reportable segments $ 166.8 $ 134.2 $ 274.4 Unallocated amounts: Interest income 0.9 0.4 5.4 Other 1.2 0.3 (2.0 ) Income from operations before income taxes 168.9 134.9 277.8 Income tax provision 43.6 54.7 101.6 Net income $ 125.3 $ 80.2 $ 176.2
Schedule Of Comparison of Balance Sheet Assets by Operating Segment	The following table sets forth a comparison of balance sheet assets by operating segment: June 30, 2016 2015 Net equipment, leasehold improvements and property: Diagnostics 26.3 34.5 Other 32.0 32.7 Total $ 58.3 $ 67.2 Total Assets: Diagnostics 512.4 450.6 Other 129.2 130.2 Total $ 641.6 $ 580.8
Summary of Assets by Geographical Region	The following table reconciles assets by geographical region: June 30, 2016 2015 Net equipment, leasehold improvements and property: United States 33.6 42.2 Rest of world 24.7 25.0 Total $ 58.3 $ 67.2 Total Assets: United States 532.6 537.3 Rest of world 109.0 43.5 Total $ 641.6 $ 580.8
Reconciliation of Assets by Operating Segment and Geographic Region to Total Assets	The following table reconciles assets by operating segment and geographic region to total assets: June 30, 2015 2015 Total assets by segment and geographical region $ 641.6 $ 580.8 Cash, cash equivalents, and marketable investment securities (1) 238.9 185.4 Total $ 880.5 $ 766.2 (1) The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments

Supplemental Cash Flow Inform41

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Years Ended June 30, 2016 2015 2014 Cash paid during the year for income taxes $ 32.0 $ 39.1 $ 108.2 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to stockholders’ equity 0.3 — (0.4 )

Organization and Summary of S42

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Proceeds from maturities and sales of marketable investment securities	$ 115.1	$ 165.6	$ 382.5
Effect of foreign exchange rates on cash and cash equivalents	(2.2)	(4.8)	(0.6)
Other receivables	3.3	1.9
Trade accounts receivables	$ 91.7	$ 85.8
Equipment | Minimum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years	5 years
Equipment | Maximum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years	7 years
Leasehold Improvements | Minimum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years	3 years
Leasehold Improvements | Maximum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years	15 years
Restatement Adjustment
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Proceeds from maturities and sales of marketable investment securities			(0.6)
Effect of foreign exchange rates on cash and cash equivalents			0.6
Other receivables			(0.6)
Trade accounts receivables			$ 0.6

Organization and Summary of S43

Organization and Summary of Significant Accounting Policies - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) - shares shares in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	70	71.3	75.7
Effect of dilutive stock options	3.4	3.2	2.5
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	73.4	74.5	78.2

Organization and Summary of S44

Organization and Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) - shares shares in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Equity [Abstract]
Anti-dilutive options and RSUs excluded from EPS computation	0	0	0

Organization and Summary of S45

Organization and Summary of Significant Accounting Policies - Schedule of Cumulative Translation Adjustments Included in Other Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]
Beginning Balance	$ (7)
Period translation adjustments	(2.6)	$ (5.2)	$ (1.7)
Ending balance	$ (9.6)	$ (7)

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Detail) € in Millions, $ in Millions	May 31, 2016USD ($)	Feb. 27, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	May 31, 2016EUR (€)
Business Acquisition [Line Items]
Increase in long-term liabilities			$ 0.6
Increase in goodwill			$ 0.6	$ (0.1)
German Clinic [Member]
Business Acquisition [Line Items]
Total cash consideration transferred		$ 20.1
Intangible asset amortization period for income tax purposes			15 years
Sividon Diagnostics GmbH
Business Acquisition [Line Items]
Total cash consideration transferred	$ 39
Business combination upfront and potential in additional performance based milestones			$ 16.7		€ 15

Business Acquisitions - Allocat

Business Acquisitions - Allocation of Consideration Transferred (Detail) - USD ($) $ in Millions	May 31, 2016	Feb. 27, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Goodwill			$ 195.3	$ 177.2	$ 169.2
German Clinic [Member]
Business Acquisition [Line Items]
Current assets		$ 3.1
Real property		20.7
Equipment		1.6
Goodwill		8.7
Current liabilities		(4.4)
Long-term liabilities		(9.6)
Total fair value purchase price		20.1
Total cash consideration transferred		$ 20.1
Sividon Diagnostics GmbH
Business Acquisition [Line Items]
Current assets	$ 2.7
Intangible assets	46.2
Equipment	0.3
Goodwill	17.7
Current liabilities	(15.4)
Total fair value purchase price	51.5
Less: Contingent consideration	(10.5)
Less: Cash acquired	(2)
Total cash consideration transferred	$ 39

Marketable Investment Securit48

Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 68.5	$ 64.1	$ 64.8	$ 104.1
Gross unrealized holding gains	0.5	0.1
Gross unrealized holding losses		(0.1)
Amortized cost	238.4	185.4
Estimated fair value	238.9	185.4
Corporate Bonds and Notes
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	50.8	41.8
Gross unrealized holding gains	0.2
Estimated fair value	51	41.8
Municipal Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	85.4	66.3
Gross unrealized holding gains	0.2	0.1
Gross unrealized holding losses		(0.1)
Estimated fair value	85.6	66.3
Federal Agency Issues
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	25.5	13.2
Estimated fair value	25.5	13.2
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	66.1	54.7
Estimated fair value	66.1	54.7
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2.4	9.4
Estimated fair value	2.4	9.4
Total Cash and Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	68.5	64.1
Estimated fair value	68.5	$ 64.1
US Government Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	8.2
Gross unrealized holding gains	0.1
Estimated fair value	$ 8.3

Marketable Investment Securit49

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	$ 68.5	$ 64.1	$ 64.8	$ 104.1
Due within one year, Amortized cost	90.5
Due after one year through five years, Amortized cost	79.4
Due after five years, Amortized cost	0
Total	238.4	185.4
Due within one year, Estimated fair value	90.5
Due after one year through five years, Estimated fair value	79.9
Due after five years, Estimated fair value	0
Total	238.9	185.4
Cash
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	66.1	54.7
Cash equivalents, Estimated fair value	66.1	54.7
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	2.4	9.4
Cash equivalents, Estimated fair value	$ 2.4	$ 9.4

Marketable Investment Securit50

Marketable Investment Securities - Schedule of Debt Securities Available-For-Sale in Gross Unrealized Loss Position (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	$ 18.6	$ 51.1
Unrealized losses, Less than 12 months		(0.1)
Fair Value, More than 12 months	7.8
Unrealized losses, More than 12 months	0	0
Fair value, Total	26.4	51.1
Unrealized losses, Total		(0.1)
Corporate Bonds and Notes
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	5	24.4
Unrealized losses, Less than 12 months		0
Fair Value, More than 12 months	1.5
Unrealized losses, More than 12 months	0	0
Fair value, Total	6.5	24.4
Unrealized losses, Total		0
Municipal Bonds
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	7.6	24.8
Unrealized losses, Less than 12 months		(0.1)
Fair Value, More than 12 months	6.3
Unrealized losses, More than 12 months	0	0
Fair value, Total	13.9	24.8
Unrealized losses, Total		(0.1)
Federal Agency Issues
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	6	1.9
Unrealized losses, Less than 12 months		0
Unrealized losses, More than 12 months	0	0
Fair value, Total	6	1.9
Unrealized losses, Total		$ 0
US Government Securities
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses, More than 12 months	$ 0

Property, Plant and Equipment51

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Land	$ 2.3	$ 2.3
Buildings and improvements	17.3	18.2
Leasehold improvements	18.7	18.5
Equipment	103.4	99.1
Gross property, plant and equipment	141.7	138.1
Less accumulated depreciation	(83.4)	(70.9)
Property, plant and equipment, net	$ 58.3	$ 67.2

Property, Plant and Equipment52

Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 14.1	$ 12.3	$ 9.2

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	May 31, 2016
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 195,300,000	$ 177,200,000	$ 169,200,000
Impairment of goodwill	0	0	0
Goodwill associated with the acquisition	17,700,000	8,100,000
Impairment of long-lived assets	0	$ 0	$ 0
2,017	14,200,000
2,018	14,200,000
2,019	14,200,000
2,020	13,800,000
2,021	13,800,000
Thereafter	134,700,000
Sividon Diagnostics GmbH
Goodwill And Intangible Assets [Line Items]
Goodwill				$ 17,700,000
Diagnostics
Goodwill And Intangible Assets [Line Items]
Goodwill	129,900,000
Diagnostics | Sividon Diagnostics GmbH
Goodwill And Intangible Assets [Line Items]
Goodwill associated with the acquisition	17,700,000
Other
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 65,400,000
Purchased Licenses and Technologies
Goodwill And Intangible Assets [Line Items]
Weighted average remaining amortization period	15 years
Customer Relationships
Goodwill And Intangible Assets [Line Items]
Estimated useful life	6 years
Weighted average remaining amortization period	15 years
Trademarks
Goodwill And Intangible Assets [Line Items]
Estimated useful life	13 years
Weighted average remaining amortization period	15 years
Developed Technology and Database | Minimum
Goodwill And Intangible Assets [Line Items]
Estimated useful life	16 years
Developed Technology and Database | Maximum
Goodwill And Intangible Assets [Line Items]
Estimated useful life	20 years

Goodwill and Intangible Asset54

Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 177.2	$ 169.2
Acquisitions	17.7	8.1
Translation adjustments	(0.2)	(0.1)
Measurement period adjustments	0.6	(0.1)
Ending balance	$ 195.3	$ 177.2

Goodwill and Intangible Asset55

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	$ 236.4	$ 206.8
Gross Carrying Amount, total intangible assets	259	211.6
Accumulated Amortization	(31.5)	(19)
Net, amortizable intangible assets	204.9	187.8
Net, total intangible assets	227.5	192.6
Net, non-amortizable intangible assets	22.6	4.8
In-Process Research and Development
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	22.6	4.8
Purchased Licenses and Technologies
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	228.7	199.1
Accumulated Amortization	(28.5)	(16.7)
Net, amortizable intangible assets	200.2	182.4
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	4.7	4.7
Accumulated Amortization	(2.4)	(1.9)
Net, amortizable intangible assets	2.3	2.8
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	3	3
Accumulated Amortization	(0.6)	(0.4)
Net, amortizable intangible assets	$ 2.4	$ 2.6

Goodwill and Intangible Asset56

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization on intangible assets	$ 12.6	$ 12.7	$ 4.6

Cost Basis Investment - Additio

Cost Basis Investment - Additional Information (Detail) - RainDance - USD ($) shares in Millions	Jun. 30, 2016	Apr. 30, 2013
Schedule of Cost-method Investments [Line Items]
Impairment on investment	$ 0
Series E Preferred Stock
Schedule of Cost-method Investments [Line Items]
Shares acquired		28
Value of shares acquired		$ 5,000,000
Series E Preferred Stock | Maximum
Schedule of Cost-method Investments [Line Items]
Percentage of total shares outstanding acquired		5.00%

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 37.3	$ 33.8
Accrued taxes payable	2.8	3.8
Other	9.4	8.5
Total accrued liabilities	$ 49.5	$ 46.1

Other Long Term Liabilities - S

Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Other Liabilities Disclosure [Abstract]
Pension obligation	$ 5.9	$ 4.9
Other	12.3	3.9
Total other long term liabilities	$ 18.2	$ 8.8

Other Long Term Liabilities - A

Other Long Term Liabilities - Additional Information (Detail) $ in Millions	Jun. 30, 2016USD ($)plan	Jun. 30, 2015USD ($)
Other Liabilities Disclosure [Abstract]
Number of defined benefit pension plans | plan	2
Fair value of plan assets	$ 0.1
Net pension liability	$ 5.9	$ 4.9

Preferred and Common Stockhol61

Preferred and Common Stockholder's Equity - Additional Information (Detail) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Class of Stock [Line Items]
Preferred stock, shares authorized	5,000,000
Preferred stock, par value	$ 0.01
Preferred stock, shares outstanding	0	0	0
Common stock, shares authorized	150,000,000
Common stock, par value	$ 0.01
Common stock, shares issued	69,100,000	68,900,000	73,500,000	80,600,000
Common stock, shares outstanding	69,100,000	68,900,000	73,500,000	80,600,000
Share repurchase program, remaining authorized repurchase amount	$ 192,300,000
Eighth Share Repurchase Program
Class of Stock [Line Items]
Share repurchase program, authorized amount	$ 200,000,000

Preferred and Common Stockhol62

Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) - shares shares in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Equity [Abstract]
Common stock issued, Beginning balance	68.9	73.5	80.6
Common stock outstanding, Beginning balance	68.9	73.5	80.6
Common stock issued upon exercise of options and employee stock plans	4.7	1.4	3.3
Repurchase and retirement of common stock	(4.5)	(6)	(10.4)
Common stock issued, Ending balance	69.1	68.9	73.5
Common stock outstanding, Ending balance	69.1	68.9	73.5

Preferred and Common Stockhol63

Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Stockholders Equity [Line Items]
Shares purchased and retired	4.5	6	10.4
Common stock and additional paid-in-capital reductions	$ 41.2	$ 51.5	$ 82.5
Charges to retained earnings	$ 121.4	$ 159.2	$ 205.1
Common Stock
Stockholders Equity [Line Items]
Shares purchased and retired	4.5	6	10.4

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Current, Federal	$ 22.2	$ 53.7	$ 97.4
Current, State	3.5	4.7	3.5
Total Current	25.7	58.4	100.9
Deferred, Federal	15.4	(2.1)	(0.7)
Deferred, State	(3.2)	8.7	0.8
Foreign	3.5	(2.3)	(2.9)
Change in valuation allowance	2.2	(8)	3.5
Total Deferred	17.9	(3.7)	0.7
Total income tax expense	$ 43.6	$ 54.7	$ 101.6

Income Taxes - Schedule of In65

Income Taxes - Schedule of Income (Loss) Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income (loss) before income taxes, United States	$ 169.5	$ 147	$ 292
Income (loss) before income taxes, Foreign	(0.6)	(12.1)	(14.2)
Income before income tax	$ 168.9	$ 134.9	$ 277.8

Income Taxes - Schedule of Diff

Income Taxes - Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported in Consolidated Statements of Operations (Detail)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Federal income tax expense at the statutory rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	2.00%	1.70%	1.60%
Research and development credits, net of the federal tax on state credits	(1.30%)	(2.50%)	(0.20%)
Uncertain tax positions, net of federal benefit	0.60%	1.20%	(0.10%)
Uncertain tax benefits statute expired, net of federal benefit	(4.40%)	0.00%	0.00%
Incentive stock option and employee stock purchase plan expense	(0.30%)	0.20%	(0.30%)
Adjustment to deferred tax liability attributable to acquired intangible assets	0.00%	1.60%	0.00%
Foreign rate differential	0.00%	1.60%	0.80%
Change in valuation allowance	1.20%	2.60%	1.20%
Basis difference, disposition of foreign subsidiary	0.00%	0.00%	(1.90%)
California basis step-up election, net of related valuation allowance impact	0.00%	(1.20%)	0.00%
Early adoption of ASU 2016-09	(7.50%)	0.00%	0.00%
Other, net	0.50%	0.40%	0.50%
Effective income tax rate	25.80%	40.60%	36.60%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Taxes [Line Items]
Non-current deferred tax assets	$ 12.7		$ 13.5
Amount of valuation allowance increased (decreased)	2.2	$ (8)
Net deferred tax liabilities	81.1	69.4
Excess tax benefits realized	12.7	3.4
Excess tax benefits attributable to deferred tax asset	54.4	61.1
Deferred tax liability not recognized, Amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries	0
Cumulative effect	$ 0
Income tax returns examination	The Company's income tax returns for the following jurisdictions are currently under examination New Jersey State income tax returns for the years ended June 30, 2007 through 2013; New York State income tax return for the years ended June 30, 2014 through 2015; and U.S. income tax return for the year June 30, 2014.
New Accounting Pronouncement, Early Adoption, Effect
Income Taxes [Line Items]
Amount of valuation allowance increased (decreased)	$ 3.8
Sividon Diagnostics GmbH
Income Taxes [Line Items]
Net deferred tax liabilities	13.2
UTAH | Prior to the adoption of Statement 123(R)
Income Taxes [Line Items]
Excess tax benefits attributable to deferred tax asset	6.8
South San Francisco, California
Income Taxes [Line Items]
Amount of valuation allowance increased (decreased)		(11.5)
Foreign net operating losses and state tax research credits
Income Taxes [Line Items]
Amount of valuation allowance increased (decreased)		3.5
Foreign Net Operating Losses
Income Taxes [Line Items]
Amount of valuation allowance increased (decreased)		$ (3.5)
State Research Tax Credit Carryforward
Income Taxes [Line Items]
Amount of valuation allowance increased (decreased)	$ 1.9

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 54.4	$ 61.1
Property, plant and equipment	1.8	2.9
Accrued vacation	2	1.7
Allowance for doubtful accounts	2.4	2.7
Stock compensation expense	27	36.8
Research and development credits	9.4	8.9
Uncertain state tax positions	1.1	1.1
Other, net	0.7	0.9
Total gross deferred tax assets	98.8	116.1
Less valuation allowance	(35.6)	(33.4)
Total deferred tax assets	63.2	82.7
Deferred tax liabilities:
Intangible assets	81.1	69.4
Total deferred tax liabilities	81.1	69.4
Net deferred tax asset		13.3
Net deferred tax liability	(17.9)
Current net deferred tax asset	0	13.5
Long term net deferred tax liability	(17.9)	(0.2)
Net deferred tax asset		$ 13.3
Net deferred tax liability	$ (17.9)

Income Taxes - Summary of Net O

Income Taxes - Summary of Net Operating Loss and Research Credit Carryforwards (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2016USD ($)
Domestic Country | Federal
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 112.3
Net operating losses subject to sections 382,383	Yes
Domestic Country | Federal | Research
Operating Loss Carryforwards [Line Items]
Research credit	$ 3.2
Research credit subject to sections 382,383	Yes
State and Local Jurisdiction | UTAH
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 209.5
Net operating losses subject to sections 382,383	No
State and Local Jurisdiction | UTAH | Research
Operating Loss Carryforwards [Line Items]
Research credit	$ 9.5
Research credit subject to sections 382,383	No
State and Local Jurisdiction | OKLAHOMA
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 14.1
Net operating losses subject to sections 382,383	Yes
Foreign (various jurisdictions)
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 30.1
Net operating losses subject to sections 382,383	No
Minimum | Domestic Country | Federal
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,027
Minimum | Domestic Country | Federal | Research
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2,025
Minimum | State and Local Jurisdiction | UTAH
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,016
Minimum | State and Local Jurisdiction | UTAH | Research
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2,021
Minimum | State and Local Jurisdiction | OKLAHOMA
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,023
Minimum | Foreign (various jurisdictions)
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration date ranges	Various
Maximum | Domestic Country | Federal
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,033
Maximum | Domestic Country | Federal | Research
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2,032
Maximum | State and Local Jurisdiction | UTAH
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,024
Maximum | State and Local Jurisdiction | UTAH | Research
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2,029
Maximum | State and Local Jurisdiction | OKLAHOMA
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2,033
Maximum | Foreign (various jurisdictions)
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration date ranges	Various

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Unrecognized tax benefits at the beginning of year	$ 26.3	$ 24.2	$ 10.9
Gross increases - current year tax positions	0.6	1.1	1.8
Gross increases - prior year tax positions	5.4	1	0.3
Gross increases - acquisitions			14.2
Gross decreases - prior year tax positions	(8.1)		(3)
Unrecognized tax benefits at end of year	24.2	26.3	24.2
Interest and penalties in year-end balance	$ 0.5	$ 0.6	$ 0.3

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Dec. 05, 2012	Sep. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Dec. 05, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description			Options and restricted stock units granted to our non-employee directors vest in full upon the earlier of (i) one full year of service on the Board following date of grant or (ii) the date of the next annual meeting of stockholders.
Options exercisable, weighted average remaining contractual life			4 years 7 months 6 days
Total unrecognized share-based compensation cost related to stock options			$ 6.5
Shares purchased under the Plan			200,000	200,000	200,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years			4 years
Total unrecognized share-based compensation cost, weighted-average period, years			10 months 24 days
Stock options | Share-based compensation granted after December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years			8 years
Stock options | Share-based compensation granted prior to December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years			10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		4 years
Total unrecognized share-based compensation cost, weighted-average period, years			2 years 3 months 18 days
Total unrecognized share-based compensation cost related to RSUs			$ 30.9
Unrecognized share-based compensation cost			$ 38.2
2012 Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved	2,000,000
Shares issued under the Plan	2,000,000
Shares purchased under the Plan			700,000
Unrecognized share-based compensation cost			$ 0.8
The 2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved						3,500,000
Shares reserved for issuance exercise of options			2,300,000
The 2010 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant			2,500,000
Chief Financial Officer [Member] | Resignation Agreement In October Two Thousand Fourteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense				$ 3.1
Chief Executive Officer [Member] | Resignation Agreement In February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense				$ 12.8

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value of Stock Option Grant with Weighted-Average Assumptions (Detail)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.40%	0.10%	0.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected lives (in years)	6 months	6 months	6 months
Expected volatility	31.00%	33.00%	56.00%
Options Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate			1.60%
Expected dividend yield			0.00%
Expected volatility			40.00%
Options Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)			4 years 1 month 6 days
Options Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)			4 years 8 months 12 days

Share-Based Compensation - Sc73

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) - $ / shares shares in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding at beginning of year, Number of shares	12.5	14.2	14.4
Options granted, Number of shares			3.3
Options exercised, Number of shares	(4.3)	(1.2)	(3.1)
Options canceled or expired, Number of shares		(0.5)	(0.4)
Options outstanding at end of year, Number of shares	8.2	12.5	14.2
Options exercisable at end of year, Number of shares	6.7	9.6	7.1
Options vested and expected to vest, Number of shares	8.2	12.5	13.4
Options outstanding at beginning of year, Weighted average exercise price	$ 23.49	$ 23.30	$ 21.75
Options granted, Weighted average exercise price			26.52
Options exercised, Weighted average exercise price	21.51	20.17	19.44
Options canceled or expired, Weighted average exercise price	0	25.98	24.30
Options outstanding at end of year, Weighted average exercise price	24.52	23.49	23.30
Options exercisable at end of year, Weighted average exercise price	24.04	22.80	21.90
Options vested and expected to vest, Weighted average exercise price	$ 24.52	$ 23.49	23.12
Weighted average fair value of options granted during the year			$ 10.04

Share-Based Compensation - Sc74

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Options Exercisable (Detail) shares in Millions	12 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at June 30,2015, Option outstanding | shares	8.2
Average remaining contractual life (years), Options outstanding	4 years 9 months 4 days
Weighted average exercise price, Options outstanding	$ 24.52
Exercisable at June 30, 2015, Options exercisable | shares	6.7
Weighted average exercise price, Options exercisable	$ 24.04
$ 9.04 - 21.29
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	9.04
Range of exercise prices, maximum	$ 21.29
Outstanding at June 30,2015, Option outstanding | shares	2.1
Average remaining contractual life (years), Options outstanding	4 years 6 months 18 days
Weighted average exercise price, Options outstanding	$ 18.25
Exercisable at June 30, 2015, Options exercisable | shares	2.1
Weighted average exercise price, Options exercisable	$ 18.25
$ 21.66 - 26.49
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	21.66
Range of exercise prices, maximum	$ 26.49
Outstanding at June 30,2015, Option outstanding | shares	3.3
Average remaining contractual life (years), Options outstanding	4 years 8 months 16 days
Weighted average exercise price, Options outstanding	$ 25.32
Exercisable at June 30, 2015, Options exercisable | shares	2.3
Weighted average exercise price, Options exercisable	$ 24.80
$ 26.84 - 30.12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	26.84
Range of exercise prices, maximum	$ 30.12
Outstanding at June 30,2015, Option outstanding | shares	2.2
Average remaining contractual life (years), Options outstanding	5 years 4 months 21 days
Weighted average exercise price, Options outstanding	$ 27.83
Exercisable at June 30, 2015, Options exercisable | shares	1.8
Weighted average exercise price, Options exercisable	$ 27.98
$ 30.34 - 37.73
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	30.34
Range of exercise prices, maximum	$ 37.73
Outstanding at June 30,2015, Option outstanding | shares	0.6
Average remaining contractual life (years), Options outstanding	3 years 3 months 4 days
Weighted average exercise price, Options outstanding	$ 30.46
Exercisable at June 30, 2015, Options exercisable | shares	0.5
Weighted average exercise price, Options exercisable	$ 30.40

Share-Based Compensation - Sc75

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) - $ / shares shares in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding at beginning of year, Number of shares	1
RSUs granted, Number of shares	0.8	1.2
RSUs released, Number of shares	(0.4)
RSUs canceled, Number of shares		(0.2)
RSUs outstanding at end of year, Number of shares	1.4	1
RSUs outstanding at beginning of year, Weighted average grant date fair value	$ 37.63
RSUs granted, Weighted average grant date fair value	40.62	$ 37.66
RSUs released, Weighted average grant date fair value	39.74	34.22
RSUs canceled, Weighted average grant date fair value		38.12
RSUs outstanding at end of year, Weighted average grant date fair value	$ 38.76	$ 37.63

Share-Based Compensation - Sc76

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 31.6	$ 45.7	$ 27.1
Molecular Diagnostic Testing Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.9	0.9	0.8
Pharmaceutical and Clinical Services Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.4	0.5	0.3
Research And Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	5.4	4.3	5.4
Selling, General, and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 24.9	$ 40	$ 27.5

Share-Based Compensation - Sc77

Share-Based Compensation - Schedule of Unrecognized Share-Based Compensation Cost (Detail) - Restricted Stock Units (RSUs) $ in Millions	Jun. 30, 2016USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation cost	$ 38.2
Aggregate intrinsic value of options outstanding	49.6
Aggregate intrinsic value of options fully vested	43.9
Aggregate intrinsic value of RSUs outstanding	$ 43.5

Share-Based Compensation - Sc78

Share-Based Compensation - Schedule of Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Total intrinsic value of options exercised	$ 86.1	$ 20.5	$ 49.4

Share-Based Compensation - Sc79

Share-Based Compensation - Schedule of Shares Purchased and Compensation Expenses (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares purchased under the plans	0.2	0.2	0.2
Plan compensation expense	$ 1.9	$ 1.8	$ 1.3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) - USD ($) $ in Millions		Jun. 30, 2016	Jun. 30, 2015
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		$ 172.8	$ 130.7
Money Market Funds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	2.4	2.4
Corporate Bonds and Notes
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		51	44.8
Municipal Bonds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		85.6	70.3
Federal Agency Issues
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		25.5	13.2
US Government Securities
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		8.3
Level 1
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		2.4	2.4
Level 1 | Money Market Funds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	2.4	2.4
Level 2
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		170.4	128.3
Level 2 | Corporate Bonds and Notes
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		51	44.8
Level 2 | Municipal Bonds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		85.6	70.3
Level 2 | Federal Agency Issues
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		25.5	$ 13.2
Level 2 | US Government Securities
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		$ 8.3
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

Commitment and Contingencies -

Commitment and Contingencies - Summary of Expended Unconditional Purchase Obligation (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2016USD ($)
Recorded Unconditional Purchase Obligation [Line Items]
Total expended on unconditional purchase obligations	$ 48.6
Fiscal Year 2014 [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Total expended on unconditional purchase obligations	10.4
Fiscal Year 2015 [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Total expended on unconditional purchase obligations	10.9
Fiscal Year 2016 [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Total expended on unconditional purchase obligations	$ 27.3

Commitment and Contingencies 82

Commitment and Contingencies - Summary of Remaining Unconditional Purchase Obligation (Detail) $ in Millions	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
Commitment for unconditional purchase obligations, 2017	$ 6.1
Total commitment for unconditional purchase obligations	$ 6.1

Commitment and Contingencies 83

Commitment and Contingencies - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2016Leases
Myriad RBM
Commitments and Contingencies [Line Items]
Non-cancelable operating leases	1
Operating leases expiration period	2,020
Administrative Functions | Minimum
Commitments and Contingencies [Line Items]
Operating leases expiration period	2,015
Administrative Functions | Maximum
Commitments and Contingencies [Line Items]
Operating leases expiration period	2,020
Information Technology Equipment
Commitments and Contingencies [Line Items]
Non-cancelable operating leases	4
Operating leases expiration period	2,018
Information Technology Equipment | Maximum
Commitments and Contingencies [Line Items]
Operating leases expiration period	2,019
Salt Lake City, Utah
Commitments and Contingencies [Line Items]
Non-cancelable operating leases	5
Salt Lake City, Utah | Minimum
Commitments and Contingencies [Line Items]
Operating leases expiration period	2,022
Salt Lake City, Utah | Maximum
Commitments and Contingencies [Line Items]
Operating leases expiration period	2,027
Germany
Commitments and Contingencies [Line Items]
Non-cancelable operating leases	1
Operating leases expiration period	2,017
Cancelable operating leases	1
Cancelable operating leases expiration period	2,018
South San Francisco, California
Commitments and Contingencies [Line Items]
Non-cancelable operating leases	1
Operating leases expiration period	2,017

Commitment and Contingencies 84

Commitment and Contingencies - Summary of Rental Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Rental expense	$ 14.3	$ 13.8	$ 11.3

Commitment and Contingencies 85

Commitment and Contingencies - Future Minimum Lease Payments (Detail) $ in Millions	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 12.9
2,018	12.6
2,019	12.1
2,020	12.4
2,021	10.6
Thereafter	41.3
Total	$ 101.9

Employee Deferred Savings Pla86

Employee Deferred Savings Plan - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

Employee Deferred Savings Pla87

Employee Deferred Savings Plan - Company's Recorded Contributions To Plan (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]
Deferred savings plan Company contributions	$ 5.5	$ 5.1	$ 4.4

Segment and Related Informati88

Segment and Related Information - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable segment	2

Segment and Related Informati89

Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 753.8	$ 723.1	$ 778.2
Depreciation and amortization	26.7	25	13.8
Segment operating income (loss)	166.8	134.2	274.4
Diagnostics
Segment Reporting Information [Line Items]
Revenues	705.7	695.5	748.2
Depreciation and amortization	21.5	20.5	9.9
Segment operating income (loss)	239.3	217.1	338
Other
Segment Reporting Information [Line Items]
Revenues	48.1	27.6	30
Depreciation and amortization	5.2	4.5	3.9
Segment operating income (loss)	$ (72.5)	$ (82.9)	$ (63.6)

Segment and Related Informati90

Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting [Abstract]
Total operating income for reportable segments	$ 166.8	$ 134.2	$ 274.4
Interest income	0.9	0.4	5.4
Other	1.2	0.3	(2)
Income before income tax	168.9	134.9	277.8
Income tax provision	43.6	54.7	101.6
Net income	$ 125.3	$ 80.2	$ 176.2

Segment and Related Informati91

Segment and Related Information - Schedule Of Comparison Of Balance Sheet Assets By Operating Segment (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	$ 58.3	$ 67.2
Total assets by segment	880.5	766.2
Operating Segments
Segment Reporting Information [Line Items]
Total assets by segment	641.6	580.8
Diagnostics
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	26.3	34.5
Total assets by segment	512.4	450.6
Other
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	32	32.7
Total assets by segment	$ 129.2	$ 130.2

Segment and Related Informati92

Segment and Related Information - Summary of Assets by Geographical Region (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	$ 58.3	$ 67.2
Total assets by geographical region	880.5	766.2
Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Total assets by geographical region	641.6	580.8
United States
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	33.6	42.2
Total assets by geographical region	532.6	537.3
Rest of World
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	24.7	25
Total assets by geographical region	$ 109	$ 43.5

Segment and Related Informati93

Segment and Related Information - Reconciliation of Assets by Operating Segment and Geographic Region to Total Assets (Detail) - USD ($) $ in Millions		Jun. 30, 2016	Jun. 30, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Assets		$ 880.5	$ 766.2
Operating segments and geographic region
Segment Reporting, Asset Reconciling Item [Line Items]
Assets		641.6	580.8
Cash, cash equivalents, and marketable investment securities
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	[1]	$ 238.9	$ 185.4
[1]	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments

Supplemental Cash Flow Inform94

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid during the year for income taxes	$ 32	$ 39.1	$ 108.2
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders' equity	$ 0.3		$ (0.4)

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Assurex Health - USD ($) $ in Millions	Aug. 03, 2016	Jun. 30, 2016
Subsequent Event [Line Items]
Business acquisition, description		The Merger Agreement contains certain termination rights for Myriad and Assurex, including the right by either party to terminate the Merger Agreement if the Merger has not occurred within two months of the signing of the Merger Agreement. The Closing is expected to occur before the end of the first quarter of Myriad’s fiscal year 2017, and is subject to customary closing conditions and regulatory approval including, among others, antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Myriad intends to fund the transaction through cash on hand and possibly short-term debt. The acquisition is not subject to a financing contingency. The Merger Agreement was approved by the Board of Directors of both Myriad and Assurex, and is conditioned on receiving the requisite stockholder approval of the Assurex stockholders.
Subsequent Event
Subsequent Event [Line Items]
Aggregate cash purchase price	$ 225
Additional payments upon completion of performance-based milestones	$ 185

Schedule of Valuation and Qua96

Schedule of Valuation and Qualifying Accounts (Detail) - Allowance for Doubtful Accounts - USD ($) $ in Millions		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		$ 7.6	$ 9	$ 7.5
Addition Changed to Cost and Expenses		33.3	31.5	39.2
Net Deductions and Other	[1]	(34.1)	(32.9)	(37.7)
Balance at End of Period		$ 6.8	$ 7.6	$ 9
[1]	Primarily represents the write-off of accounts receivables net of recoveries.